



DIASORIN S.P.A. ANNOUNCED TODAY THE CLOSING OF THE TRANSACTION TO ACQUIRE THE MUREX® PRODUCT LINE

Saluggia (Vercelli, Italy), June 1, 2010 – DiaSorin S.p.A., a global leader in the immunodiagnostics market, announced today the closing of the transaction to acquire the MUREX® product line from Abbott, initiated with a binding agreement signed on the 10th of March (as simultaneously announced).

As previously announced, the MUREX® product line consists of products for the diagnosis of HIV, HCV and HBV infections. Assets dedicated to the manufacture of these products, which are located in South Africa and the UK, are included in the transaction. MUREX® products generated approximately \$66.7 million for the year ended December 31, 2009. The transaction does not include commercial payables and receivables that will remain with the seller.

The purchase price, as already stated, is \$58 million cash and it will be funded entirely with internal Company resources.

This acquisition, consistent with DiaSorin's strategy to continue to add new depth to its product portfolio, further strengthens its leadership position in infectious disease and open the door for attractive growth opportunities in the future.



About DiaSorin

DiaSorin S.p.A., an international player in the market for in vitro diagnostics, develops, produces and markets reagent kits for clinical laboratory diagnostics. The DiaSorin Group is comprised of 20 companies based in Europe, the United States, Central and South America and Asia. It has more than 1,100 employees, including about 110 research and development specialists, and operates four manufacturing and research facilities in Saluggia (Vercelli, Italy), Dietzenbach (Germany), Stillwater (USA) and Dublin (Ireland). Thanks to its direct sales organization and an international network of over 80 independent distributors, the Group is present in more than 60 countries, offering a broad array of high quality products that includes comprehensive lines for each of the clinical segments in which it operates: infectious and viral diseases, management of bone and calcium related diseases, thyroid pathologies, oncology and fertility testing.

For additional information, please visit our website: www.diasorin.it

Contacts:

Investor Relations Officer

Laura Villa

DiaSorin S.p.A.

laura.villa@diasorin.it

+39 0161487532

+39 348 15 11 542

Press Office

Carolina Mailander

c.mailander@mailander.it

+39 335 655 56 51

Bruno Caprioli

caprioli@mailander.it

+39 335 590 14 02